Albana Gattelli, Ivan Nalvarte, Anne Boulay, Tim C. Roloff, Martin Schreiber, Neil Carragher, Kenneth K. Macleod, Michaela Schlederer, Susanne Lienhard, Lukas Kenner, Maria I. Torres-Arzayus and Nancy E. Hynes Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells EMBO Molecular Medicine 5
Article first published online: 19 JUL 2013 | DOI: 10.1002/emmm.201302625
Receptor tyrosine kinases (RTK) are validated targets for cancer therapy, but only subsets of patients are eligible for this treatment. Ret inhibition blocks a novel Ret-IL6 feed-forward loop, tumor growth and metastasis of ER+ breast cancers.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field